메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Complete Genomics Highlights New Products, Partnerships, First DNBSEQ User Group Meeting at ASHG 2025

BOSTON, Oct. 14, 2025 -- Complete Genomics, a leading innovator in genomic sequencing, today announced a series of milestones at the American Society of Human Genetics (ASHG) Annual Meeting, Oct. 14–18, 2025 in Boston. At ASHG 2025, for the first time, Complete Genomics will host a DNBSEQ™ User Group Meeting to bring together researchers and customers to share best practices, explore applications across oncology, rare disease and population genomics, and hear updates from the company on product innovations. The meeting will take place on Tuesday, Oct. 14, 2025, 8:30 a.m. - 5:00 p.m. ED
- 김갑성 기자
- 2025-10-14 21:00
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 -- Indian Institute of Technology Madras (IIT Madras), India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pioneering initiative dedicated to transforming paediatric cancer care in India. As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor
- 김갑성 기자
- 2025-10-14 20:30
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care

CHENNAI, India, Oct. 14, 2025 -- Indian Institute of Technology Madras (IIT Madras), India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pioneering initiative dedicated to transforming paediatric cancer care in India. As part of its multi-year commitment towards this cause, HMIF has allocated a social impact investment of INR 56 Crore towards this landmark project. HMIL is the Indian arm of the South Korean automaker Hyundai Motor
- 김갑성 기자
- 2025-10-14 20:30
Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"

[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing, Zhejiang, bringing together a prestigious gathering of leading minds in the field. Attendees included Chinese Academy of Engineering academicians Zhang Xingdong and Wang Yingjun, Chinese Academy of Sciences academicians Chen Xuesi, Tang Peifu, and Chen Chunying, alongside renowned international experts such as U.S. National Academy of Engineering member Leonar
- 김갑성 기자
- 2025-10-14 20:30
Asia University Partners with NucleicAI to Build a Sovereign AI Life Science Data Platform

TAICHUNG, Oct. 14, 2025 -- Asia University will partner with NucleicAI LLC, a next-generation platform and data company specializing in AI-driven genomics, precision medicine, and health intelligence, to build a Sovereign AI Life Science Data Platform in Taiwan. The platform will be hosted in-country, supporting secure data sharing, advanced analytics, and research collaboration while preserving data sovereignty. The signing of the Memorandum of Understanding took place at the IEEE International Conference on AI × Medicine, Health, and Care in Taichung, featuring a keynot
- 김갑성 기자
- 2025-10-14 20:00
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA

SHANGHAI, Oct. 14, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly optimized structure integrates three key elements: - Mab0727: A highly specific CDH17 monoclonal antibody with rapid int
- 김갑성 기자
- 2025-10-14 20:00
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed -- -- Interim analysis from RSV re-vaccination trial demonstrates ≥60% higher trend in RSV neutralizing antibodies for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) i
- 김갑성 기자
- 2025-10-14 18:18
Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it has been awarded a £1.2 billion, 15-year contract by the NHS Business Services Authority (NHSBSA) to deliver the Future NHS Workforce Solution. Infosys will develop a cutting-edge, data-driven workforce management solution that will replace the current Electronic Sta
- 김갑성 기자
- 2025-10-14 18:02
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

[ 메디채널 김갑성 기자 ] - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne
- 김갑성 기자
- 2025-10-14 18:00
Kyoto University Engineering Ph.D. Team Realizes Achievement Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"

[ 메디채널 김갑성 기자 ] —— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing, Zhejiang, gathering leading experts including academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, together with international figures such as U.S. National Academy of Engineering member Leonard Pinchuk, UK Royal Society Fellow Molly Stevens, and Professor Kunio Ishikawa, President of the Japanese Society for Biomaterials.&
- 김갑성 기자
- 2025-10-14 17:22

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-11-04_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 04일 19시 40분